Last year Destiny Pharma initiated a dermal infection clinical programme with its XF-73 anti-infective targeting diabetic foot ulcer infections. Phase 1 of this programme for the prevention of post-surgical infections has been successfully completed and the protocol for phase 2b, due to start in April 2019, has been finalised.
US Market research reports have confirmed the clinical need and attractive target product profile of the XF-73 nasal product. The FDA has also granted Fast Track designation for XF-73 and awarded the company a UK China AMR grant of up to £1.6m to examine XF compounds potential against dermal and ocular infections.
Neil Clark, CEO of Destiny Pharma, stated that “There is continuing international support for the development of novel anti-infective drugs that address the issue of anti-microbial resistance and Destiny Pharma’s unique platform is well-positioned to meet this global need.”